secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001104659-23-113580
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics secures up to $40M non-dilutive royalty financing with HealthCare Royalty
--------------------------------------------------------------------------------

- Upfront cash payment of $17.5M; up to $20M additional if Kapruvia gets a German price threshold in Q4 2023.
- Up to $2.5M more if KORSUVA meets a 2024 Japan sales milestone; total potential proceeds $40M.
- Cash runway expected to extend into 2025; proceeds fund late-stage oral difelikefalin trials for pruritus.
- Royalties to HCRx are capped at 2.0x payments if received by end-2029, else 2.8x; royalties revert to Cara thereafter.
- Excluded: U.S. KORSUVA injection rights and all oral difelikefalin internal programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923113580/0001104659-23-113580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923113580/tm2329618d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer